CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

AstraZeneca (LSE:AZN) Secures Zegfrovy In $1.5 Billion Lung Cancer Licensing Deal

PartnershipZegfrovyPositive
AI Analysis

Summary

AstraZeneca secured Zegfrovy, a lung cancer drug, through a $1.5 billion licensing deal, expanding its oncology portfolio.

Importance:7/10
Sentiment:
0.70
licensing deallung canceroncologyacquisition
Related Companies

Read the original article

Published by yahoo_finance on July 15, 2026 1:12 PM

Read Original